Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 43,848 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average price of $12.24 per share, for a total transaction of $536,699.52. Following the purchase, the director now owns 17,255,151 shares in the company, valued at $211,203,048.24. The trade was a 0.25 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Monday, March 24th, Ecor1 Capital, Llc bought 22,689 shares of Zymeworks stock. The stock was purchased at an average cost of $13.08 per share, for a total transaction of $296,772.12.
- On Friday, March 21st, Ecor1 Capital, Llc purchased 31,033 shares of Zymeworks stock. The stock was purchased at an average price of $12.78 per share, with a total value of $396,601.74.
- On Wednesday, March 19th, Ecor1 Capital, Llc acquired 58,306 shares of Zymeworks stock. The shares were purchased at an average price of $12.64 per share, for a total transaction of $736,987.84.
- On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The stock was acquired at an average price of $12.23 per share, for a total transaction of $688,267.71.
- On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was acquired at an average price of $12.48 per share, with a total value of $5,845,082.88.
- On Tuesday, March 11th, Ecor1 Capital, Llc purchased 320,690 shares of Zymeworks stock. The stock was acquired at an average price of $11.49 per share, with a total value of $3,684,728.10.
- On Friday, January 17th, Ecor1 Capital, Llc bought 19,748 shares of Zymeworks stock. The shares were bought at an average price of $13.87 per share, with a total value of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc purchased 39,029 shares of Zymeworks stock. The stock was bought at an average cost of $14.01 per share, with a total value of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The stock was purchased at an average cost of $13.39 per share, for a total transaction of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were purchased at an average price of $13.13 per share, with a total value of $2,679,806.74.
Zymeworks Price Performance
Zymeworks stock opened at $12.51 on Friday. The firm has a market cap of $870.41 million, a P/E ratio of -8.34 and a beta of 1.13. The stock's 50 day moving average is $13.63 and its 200 day moving average is $13.71. Zymeworks Inc. has a one year low of $7.97 and a one year high of $17.70.
Analyst Ratings Changes
Several analysts recently weighed in on ZYME shares. Citigroup upped their price objective on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Wells Fargo & Company raised their price target on shares of Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. JPMorgan Chase & Co. upgraded shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price target for the company in a report on Monday, December 16th. Lifesci Capital assumed coverage on Zymeworks in a report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price objective on the stock. Finally, HC Wainwright upped their target price on Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.
Check Out Our Latest Research Report on ZYME
Institutional Investors Weigh In On Zymeworks
A number of institutional investors have recently modified their holdings of ZYME. Deutsche Bank AG lifted its holdings in Zymeworks by 1.2% in the fourth quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock valued at $22,645,000 after buying an additional 17,849 shares during the period. State Street Corp grew its stake in Zymeworks by 6.1% during the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock worth $14,706,000 after purchasing an additional 67,401 shares during the period. Dimensional Fund Advisors LP increased its holdings in Zymeworks by 14.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company's stock worth $14,240,000 after purchasing an additional 123,240 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in Zymeworks by 2.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company's stock worth $11,121,000 after purchasing an additional 17,092 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Zymeworks by 93.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after buying an additional 311,107 shares in the last quarter. 92.89% of the stock is owned by institutional investors.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
